ARCT — Arcturus Therapeutics Holdings Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1768224 ·
Last close
$7.21
Market Cap
$204.93M
52W High
$9.58
52W Low
$6.36
ADV30
410,940
Next earnings
2026-05-07
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 610,000 | — | -28,931,000 | -26,964,000 | 245,411,000 | 211,375,000 | 54,049,000 |
| Dec 2025 | 3,081,000 | — | -31,307,000 | -29,079,000 | 271,148,000 | 230,909,000 | 57,163,000 |
| Sep 2025 | 14,153,000 | — | -16,512,000 | -13,448,000 | 282,343,000 | 180,360,000 | 57,784,000 |
| Jun 2025 | 24,510,000 | — | -11,616,000 | -9,180,000 | 309,270,000 | 196,467,000 | 78,217,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-74,271,000
Investing CF
$-230,000
Financing CF
$13,382,000
CapEx
$-398,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.38
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-514,590,000
Inventory
—
Receivables
$5,564,000
ST Investments
—
EBIT TTM
$-65,775,000
Pretax Income TTM
$-65,783,000
Interest Exp TTM
$0
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$54,710,000
EBITDA
$-85,483,000
Free Cash Flow
$11,289,250
Enterprise Value
$12,426,175
Total Cash
$211,375,008
Total Debt
$23,987,000
Shares Out
28,423,069
Trailing EPS
$-2.83
Book Value
$6.73
ROE
-37.0%
ROA
-19.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 67,221,000 | -76,260,000 | -65,783,000 | 271,148,000 | 57,163,000 | — | -74,271,000 |
| Dec 2024 | 138,389,000 | -95,669,000 | -80,941,000 | 344,069,000 | 103,091,000 | — | -59,747,000 |
| Dec 2023 | 157,748,000 | -78,205,000 | -29,725,000 | 429,402,000 | 150,889,000 | — | -18,099,000 |
| Dec 2022 | 205,755,000 | 12,177,000 | 9,349,000 | 450,387,000 | 180,075,000 | — | 31,993,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.99
Max Pain — expiry 2026-06-18
max pain strike: $7.50 · spot: $7.21 · call oi: 3,258 · put oi: 1,599
Expected Move to 2026-06-18:
±$1.35
(18.72%) —
implied range
$5.86 –
$8.56
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TNXP | Tonix Pharmaceuticals Holding Corp. | $203.56M | $12.77 | — |
| KPTI | Karyopharm Therapeutics Inc. | $203.29M | $8.97 | — |
| CAMP | Camp4 Therapeutics Corp | $212.90M | $4.10 | — |
| NBP | NovaBridge Biosciences | $215.11M | $1.86 | — |
| TLSA | Tiziana Life Sciences Ltd | $192.16M | $1.51 | — |
News headlines (Yahoo Finance, 1h cache)
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
2026-05-26 20:01 · Yahoo
Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary
2026-05-08 12:30 · Yahoo
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 21:55 · Yahoo
Arcturus Therapeutics Q1 Earnings Call Highlights
2026-05-07 21:39 · Yahoo
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
2026-05-07 20:01 · Yahoo
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
2026-04-27 20:01 · Yahoo
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
2026-03-25 15:12 · Yahoo
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf
2026-03-23 18:47 · Yahoo
These Are the Only 3 Stocks That Cathie Wood Bought Last Week
2026-03-23 11:27 · Yahoo
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing
2026-03-12 06:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.